<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712983</url>
  </required_header>
  <id_info>
    <org_study_id>CTBM100G2202</org_study_id>
    <secondary_id>2015-003040-39</secondary_id>
    <nct_id>NCT02712983</nct_id>
  </id_info>
  <brief_title>Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection</brief_title>
  <acronym>iBEST-1</acronym>
  <official_title>A Randomized, Blinded, Parallel Group, Multi-center Dose-finding Study, to Assess the Efficacy, Safety and Tolerability of Different Doses of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen's University Belfast, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Antwerp, BE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan, IT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion Clinic per a la Recerca Biomedica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Papworth Hospital Cambridge, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brompton Hospital Trust, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Edinburgh, UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to support the selection of a safe and tolerable tobramycin
      inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P.
      aeruginosa in non-cystic fibrosis bronchiectasis (BE) patients with P. aeruginosa
      colonization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a blinded, randomized, dose- and regimen finding trial where active TIP doses or
      placebo is given in addition to the local standard care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2017</start_date>
  <completion_date type="Actual">March 20, 2019</completion_date>
  <primary_completion_date type="Actual">March 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>P. aeruginosa density in sputum</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Change in P. aeruginosa bacterial load in sputum as assessed by the change in log10 colony forming units (CFUs) from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of pulmonary exacerbations</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Defined as frequency of pulmonary exacerbations compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first use of antipseudomonal antibiotics</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Measured by the time to first use of anti-pseudomonal antibiotics compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum tobramycin concentration</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum tobramycin concentration</measure>
    <time_frame>Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P. aeruginosa density in sputum over the entire study duration</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Change in P. aeruginosa bacterial load in sputum from baseline as assessed by the change in colony forming units (CFUs) of P. aeruginosa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Symptom Scale Quality of Life Questionnaire for Bronchiectasis (QOL-B)</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Change from baseline on the Respiratory Symptom Scale QOL-B. Respiratory Symptoms is 1 out of 8 domains of the QOL-B instrument and is graded on a 4-point Likert scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pulmonary exacerbations</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Defined as rate of pulmonary exacerbations compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of pulmonary exacerbations</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Defined as severity of pulmonary exacerbations compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of pulmonary exacerbations</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Defined as time to onset of pulmonary exacerbations compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring anti-pseudomonal antibiotics</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Measured by proportion of patients requiring anti-pseudomonal antibiotics compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of anti-pseudomonal antibiotic treatment</measure>
    <time_frame>112 days of treatment and 56 days of follow-up</time_frame>
    <description>Measured by duration of use of anti-pseudomonal antibiotics compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Non-cystic Fibrosis Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>TIP dose regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin inhalation powder (TIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIP and placebo dose regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin inhalation powder (TIP) and inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose regimen 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIP dose regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin inhalation powder (TIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIP and placebo dose regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin inhalation powder (TIP) and inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose regimen 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIP dose regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin inhalation powder (TIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIP and placebo dose regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin inhalation powder (TIP) and inhaled placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose regimen 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP</intervention_name>
    <description>TIP dose regimen</description>
    <arm_group_label>TIP dose regimen 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP and placebo</intervention_name>
    <description>TIP and inhaled placebo dose regimen</description>
    <arm_group_label>TIP and placebo dose regimen 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled placebo dose regimen</description>
    <arm_group_label>Placebo dose regimen 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP</intervention_name>
    <description>TIP dose regimen</description>
    <arm_group_label>TIP dose regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP and placebo</intervention_name>
    <description>TIP and inhaled placebo dose regimen</description>
    <arm_group_label>TIP and placebo dose regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled placebo dose regimen</description>
    <arm_group_label>Placebo dose regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP</intervention_name>
    <description>TIP dose regimen</description>
    <arm_group_label>TIP dose regimen 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIP and placebo</intervention_name>
    <description>TIP and inhaled placebo dose regimen</description>
    <arm_group_label>TIP and placebo dose regimen 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled placebo dose regimen</description>
    <arm_group_label>Placebo dose regimen 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained before any assessment is performed.

          -  Male and female patients of ≥ 18 years of age at screening (Visit 1).

          -  Proven diagnosis of non-CF BE as documented by computed tomography or high-resolution
             computed tomography

          -  At least 2 or more exacerbations treated with oral antibiotics OR 1 or more
             exacerbation requiring intravenous antibiotic treatment within 12 months prior to
             screening.

          -  FEV1 ≥ 30% predicted at screening (Visit 1).

          -  P. aeruginosa, must be documented in a respiratory sample at least 1 time within 12
             months and also present in the expectorated sputum culture at Visit 1.

        Exclusion Criteria:

          -  Patients with a history of cystic fibrosis.

          -  Patients with a primary diagnosis of bronchial asthma.

          -  Patients with a primary diagnosis of COPD associated with at least a 20 pack year
             smoking history.

          -  Any significant medical condition that is either recently diagnosed or was not stable
             during the last 3 months, other than pulmonary exacerbations, and that in the opinion
             of the investigator makes participation in the trial against the patients' best
             interests.

          -  Clinically significant (in the opinion of the investigator) hearing loss that
             interferes with patients' daily activities (such as normal conversations) or chronic
             tinnitus. Patients with a past history of clinically significant hearing loss in the
             opinion of the investigator may be eligible only if their hearing threshold at
             screening audiometry is 25dB or lower at frequencies 0.5-4 kHz. The use of a hearing
             device is reflective of a clinically significant hearing loss; hence patients using
             hearing aids at screening are not eligible.

          -  Patients with active pulmonary tuberculosis.

          -  Patients currently receiving treatment for nontuberculous mycobacterial (NTM)
             pulmonary disease.

          -  Patients who are regularly receiving inhaled anti-pseudomonal antibiotic (during the
             study inhaled anti-pseudomonal antibiotics are not allowed other than the study drug).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bayonne</city>
        <state>Bayonne Cedex</state>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice</city>
        <state>Cedex1</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <state>Herault</state>
        <zip>34059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pordenone</city>
        <state>PN</state>
        <zip>33170</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milan</city>
        <zip>20112</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Scafati</city>
        <zip>84018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunitat Valencia</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baracaldo - Vizcaya</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dundee</city>
        <state>Perthshire</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edinburgh</city>
        <zip>ED16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lancaster</city>
        <zip>LA1 4RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inhaled tobramycin; tobramycin inhalation powder; bronchiectasis; pulmonary Pseudomonas aeruginosa infection; dose-finding study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>March 17, 2020</submitted>
    <returned>April 1, 2020</returned>
    <submitted>May 29, 2020</submitted>
    <returned>June 18, 2020</returned>
    <submitted>June 19, 2020</submitted>
    <returned>July 8, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

